Streetbeat News

SAVA

Cassava Sciences, Inc.

https://www.cassavasciences.com

Industry

Biotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Open

26.46

Mkt cap

1.3B

Volume

2.8M

High

28.99

P/E Ratio

-19.50

52-wk high

42.20

Low

25.46

Div yield

N/A

52-wk low

8.79

Despite a general downward trend in U.S. stocks, several companies recorded gains. Olink Holding AB's shares rose 65.8% after Thermo Fisher Scientific announced plans to acquire the company. Wyndham Hotels & Resorts, Inc. gained 11.2% following a proposal from Choice Hotels to acquire the company for $90.00 per share. Engaged Capital has built a significant stake in V.F. Corporation, leading to a 13.4% rise in its shares. Sensient Technologies Corporation's stock jumped 6.7% after Baird upgraded the stock from Neutral to Outperform.

Portfolio Pulse from Lisa Levin

October 17, 2023 | 3:40 pm

The article lists the stocks that gained and lost the most during Friday's mid-day trading session. Among the gainers were Sigma Additive Solutions, Bio-Path Holdings, and Shift Technologies, while the losers included Bellerophon Therapeutics, Outset Medical, and MSP Recovery. The article also mentions several companies that reported better-than-expected earnings, such as Comtech Telecommunications and JPMorgan Chase, and others that lowered their guidance or reported worse-than-expected results, such as Belden and SMART Global Holdings.

Portfolio Pulse from Lisa Levin

October 13, 2023 | 5:14 pm

The UK's Competition and Markets Authority has approved Microsoft's $69B acquisition of Activision Blizzard. Google is testing generative AI functionalities for its search tool. Cassava Sciences faces controversy over scientific misconduct allegations. Ford is struggling with UAW negotiations. EHang shares are trading higher after obtaining a certificate for its EH216-S UAV system. OpenAI is valued at $90B and is close to selling shares. TSMC is seeking permanent US approval for chip supplies. Netflix plans to launch 'Netflix House' experiences. The Kroger-Albertsons deal faces potential legal challenges. Boeing and Spirit AeroSystems are inspecting 737 Max aircraft defects. Wells Fargo, JPMorgan, Citigroup, BlackRock, and UnitedHealth reported Q3 earnings. Porsche records a 10% surge in deliveries for the first three quarters.

Portfolio Pulse from Vandana Singh

October 13, 2023 | 1:48 pm

During Friday's pre-market session, several healthcare stocks experienced significant movement. Bio-Path Hldgs, Redhill Biopharma, Akari Therapeutics, TRACON Pharma, Petros Pharma, and Sera Prognostics saw increases in their stock prices. Conversely, Outset Medical, Nuwellis, Bellerophon Therapeutics, Cassava Sciences, OpGen, and Reshape Lifesciences experienced decreases.

Portfolio Pulse from Benzinga Insights

October 13, 2023 | 1:06 pm

Cassava Sciences' shares are trading lower following a report by the City University of New York that implicated a long-time collaborator of the company in scientific misconduct related to 20 research papers.

Portfolio Pulse from Bill Haddad

October 13, 2023 | 12:27 pm

Cassava Sciences Inc (NASDAQ:SAVA) is facing controversy as a recent investigation by the City University of New York (CUNY) has implicated neuroscientist Hoau-Yan Wang, a long-time collaborator of Cassava, in scientific misconduct related to 20 research papers. These papers were crucial in advancing simufilam, the company's lead Alzheimer's program. The investigation could not definitively prove its suspicions as Dr. Wang did not provide the original raw data. Last year, the U.S. Justice Department opened a criminal investigation into Cassava Sciences on whether it manipulated research results for its investigational Alzheimer's drug.

Portfolio Pulse from Vandana Singh

October 13, 2023 | 11:39 am

Shares of several companies including Oblong, Bio-Path Holdings, Blue Star Foods, Versus Systems, RedHill Biopharma, Datasea, Shift Technologies, Getaround, Scienjoy Holding, and Comtech Telecommunications surged in pre-market trading. Comtech's shares rose after posting better-than-expected Q4 results. On the other hand, shares of Cassava Sciences, SMART Global Holdings, BeyondSpring, Edesa Biotech, ReShape Lifesciences, Momentus, LogicMark, Society Pass, Tian Ruixiang Holdings, and ParaZero Technologies fell in pre-market trading.

Portfolio Pulse from Lisa Levin

October 13, 2023 | 11:35 am

Several US stocks traded lower in Friday's pre-market session. Outset Medical, Inc. (OM) fell 38.1% after reporting preliminary Q3 financial results. Cassava Sciences, Inc. (SAVA) shares dipped 28.8% following a statement regarding a leaked internal CUNY report. SMART Global Holdings, Inc. (SGH) declined 25.8% after reporting worse-than-expected Q4 financial results and a weak Q1 forecast. Puyi Inc. (PUYI), Nextdoor Holdings, Inc. (KIND), AvePoint, Inc. (AVPT), and JD.com, Inc. (JD) also recorded losses.

Portfolio Pulse from Lisa Levin

October 13, 2023 | 10:37 am

Cassava Sciences has issued a statement regarding a leaked internal report from the City University of New York (CUNY). The company states that there were no findings of data manipulation in the report.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 7:02 am

Several healthcare stocks experienced significant movement in Thursday's after-market session. Bio-Path Hldgs, Comera Life Sciences, Scinai Immunotherapeutics, 60 Degrees, Bellerophon Therapeutics, and Relay Therapeutics saw increases, while Cassava Sciences, Outset Medical, T2 Biosystems, OpGen, Tempest Therapeutics, and BeyondSpring saw decreases.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 9:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.